Funding (Updated 07/17/2014)

Funding (Updated 07/17/2014)

Find information below about:

  • External Funding Opportunities
  • Internal Funding Opportunties
  • Active Requests for Information

External Funding Opportunities

2015 Center of Excellence for Comparative Effectiveness Research Education


The purpose of this program is to provide funding to a U.S. educational institution in order for it to develop or expand a degree-granting program in comparative effectiveness research (CER). Organizations/institutions eligible to apply include those academic degree granting programs with an existing NIH or AHRQ-funded CER research or training program and the capacity to develop a degree-granting program in CER using existing tenure track professors.

    Letter of Intent Due Date: Not applicable
    Application Due Date: September 1, 2014.

Scientific/Research Contact:
Ms. Eileen Cannon, Executive Director,
Pharmaceutical Research and Manufacturers of America Foundation
foundation@phrma.org
202.572.7756


2015 PhRMA Research and Training Awards 


Adherence Application Deadline : 09-01-2014
Informatics     Application Deadline : 09-01-2014
Health Outcomes Application Deadline : 02-01-2015
Pharmacology/Toxicology Application Deadline : 09-01-2014
Pharmaceutics Application Deadline : 09-01-2014
Clinical Pharmacology Application Deadline : 02-01-2015 Translational Medicine and Therapeutics Application Deadline : 02-01-2015

The PhRMA Foundation funds scientists at critical points in their research careers to support and reward innovation in disciplines essential to the development of safe and effective medicines. The PhRMA Foundation offers competitive pre and post doctoral fellowships, sabbatical fellowships, and research starter grants to advance science in Adherence Improvement, Clinical Pharmacology, Comparative Effectiveness Research, Health Outcomes, Informatics, Pharmaceutics, Pharmacology/Toxicology, and Translational Medicine and Therapeutics.

High Throughput Screening (HTS) to Discover Chemical Probes

     PAR-14-283       R21
     PAR-13-134      X01 
     PAR-13-135      R03
     PAR-14-284      R01 

These Funding Opportunity Announcements (FOAs) encourages investigators to form collaborations with an established academic, nonprofit, or commercial high throughput screening (HTS) facility that has the requisite expertise and experience to implement HTS-ready assays for the discovery and development of small molecule chemical probes. NIH wishes to stimulate research in 1) discovery and development of novel, small molecules for their potential use in studying disease treatments relevant to the missions of the participating NIH Institutes, and 2) discovery and/or validation of novel, biological targets that will inform studies of disease mechanisms.  Emphasis will be placed on projects that provide new insight into important disease targets and processes. 

    Letter of Intent Due Date: 30 days prior to deadline
    Application Due Date: Standard dates apply (until 09/08/17)​

Scientific/Research Contact:
See RFA.


Pilot Centers for Precision Disease Modeling (U54)


This Funding Opportunity Announcement (FOA) invites U54 cooperative agreement applications for Pilot Centers for Precision Disease Modeling. The goal of the Centers is to support collaborative research projects that link current personalized medicine efforts in human subjects with advances in animal genomics and technologies for genetic manipulation and creation of interspecies somatic hybrids. Functionally linking these areas of research will produce programs to enhance the predictive value of pre-clinical studies based on the use of precision animal models. Centers will establish demonstration pipelines for pre-clinical scientific discovery, disease modeling, and development of interventions based on innovative animal models. These preclinical pipelines eventually will be an integral part of diagnostics, care and therapeutic treatment of patients. Each Center should have a set of required components: a Coordination Section to assure effective multidisciplinary leadership; a Pre-clinical/Co-clinical Section to collect and distribute patient information; a Bioinformatics Section to provide diverse computational abilities; and, as a major emphasis, a Disease Modeling Unit for the creation and testing of at least three precision animal projects. Even though the centers will work on a limited number of focused projects, it is expected that the program will maintain multifaceted research activities to build core model systems that can be adjusted as required to accommodate a broad spectrum of diseases.  

    Letter of Intent Due Date: Not applicable
    Application Due Date: October 1, 2014, 5pm CT 

Scientific/Research Contact:
Oleg Mirochnitchenko, Ph.D.
Office of Research Infrastructure Programs (ORIP)
Telephone: 301-435-0749 
Email: oleg.mirochnitchenko@mail.nih.gov

Ethical, Legal, and Social Implications (ELSI) of Genomic Research
    Exploratory/Developmental Research Program (R21)  PA-14-278    
    Regular Research Program (R01)    PA-14-276
    Small Research Grant Program (R03)    PA-14-277    

This Funding Opportunity Announcement (FOA) invites Exploratory / Developmental Research Program Grant (R21) applications that propose to study the ethical, legal and social implications (ELSI) of human genome research.  Applications should propose exploratory or developmental studies that break new ground or extend previous discoveries in new directions.  Of particular interest are studies that explore the implications of new or emerging genomic technologies or novel uses of genomic information. 

    Letter of Intent Due Date: Not applicable
    Application Due Date: Standard NIH deadlines apply (until 09/08/17) 

Scientific/Research Contact:
See Program Annnouncement for list of Institute specific contacts

 
Discovery of in vivo Chemical Probes (R01)


This Funding Opportunity Announcement (FOA) intends to support investigators who have interest and capability to join efforts for the discovery of in vivo chemical probes. It is expected that applicants will have in hand the starting compounds (“validated hits”) for chemical optimization and bioassays for testing new analog compounds. Through this FOA, NIH wishes to stimulate research in 1) discovery and development of novel, small molecules for their potential use in studying disease treatment relevant to the missions of the participating NIH Institutes, and 2) discovery and/or validation of novel, biological targets that will inform studies of disease mechanisms.  Emphasis will be placed on projects that provide new insight into important disease targets and processes. 

    Letter of Intent Due Date: 30 days prior to due date
    Application Due Date: Standard NIH deadlines apply (until 09/07/17) 

Scientific/Research Contact:
See Program Annnouncement for list of Institute specific contacts


Career Awards for Medical Scientists (Burroughs Wellcome Fund)


The Career Awards for Medical Scientists (CAMS) is a highly competitive program that provides $700,000 awards over five years for physician-scientists, who are committed to an academic career, to bridge advanced postdoctoral/fellowship training and the early years of faculty service. Proposals must be in the area of basic biomedical, disease-oriented, or translational research.  Proposals in health services research or involving large-scale clinical trials are not eligible.

    INTERNAL UAB DEADLINE: August 10, 2014, 5pm CT
        Please see left column for guidance on limited institutional submissions
    Application Due Date: October 1, 2014, 3pm CT
    
Scientific/Research Contact:
Rolly Simpson, Sr. Program Officer
919/991-5110

Debra Holmes, Sr. Program Assoc.
919/991-5134

Kendra Tucker, Sr. Program Asst.
919/991-5115

 Investigators in the Pathogenesis of Infectious Disease (Burroughs Wellcome Fund)


This award provides $500,000 over a period of five years to support accomplished investigators at the assistant professor level to study pathogenesis, with a focus on the interplay between human and microbial biology, shedding light on how human and microbial systems are affected by their encounters. The awards are intended to give recipients the freedom and flexibility to pursue new avenues of inquiry and higher-risk research projects that hold potential for significantly advancing the biochemical, pharmacological, immunological, and molecular biological understanding of how microbes and the human body interact.

    INTERNAL UAB DEADLINE: September 10, 2014, 5pm CT
        Please see left column for guidance on limited institutional submissions
     Application Due Date: November 3, 2014, 3pm CT

Scientific/Research Contact:
Victoria McGovern, Ph.D., Sr. Program Officer
919/991-5112

Jean Kramarik, Sr. Program Assoc.
919/991-5122

Ruth Reynolds, Program Asst.
919/991-5129

Comparative Health System Performance in Accelerating PCOR Dissemination (U19)


As part of AHRQ's PCOR dissemination efforts, this AHRQ Funding Opportunity Announcement (FOA) invites applications for Centers of Excellence to identify, classify, track, and compare healthcare delivery systems ranging from integrated delivery systems to Accountable Care Organizations across the U.S. to help improve the speed of adoption and diffusion of CER-recommended practices through systems. 

    Letter of Intent Due DateSeptember 5, 2014
    Application Due Date: October 17, 2014 by 5PM CT

Scientific/Research Contact:​
William Encinosa, Ph.D.
Center for Delivery, Organization, and Markets
Agency for Healthcare Research and Quality
Telephone:  301-427-1437
Email address:  william.encinosa@ahrq.hhs.gov 


Development of Novel Therapeutics for Select Pathogens (R21/R33) 


The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications to support basic to translational research focused on development of novel therapeutics against select antibiotic-resistant gram-negative bacteria or influenza. 

    Letter of Intent Due DateSeptember 19, 2014  
    Application Due Date: October 20, 2014, by 5:00 PM 

Scientific/Research Contact:​
Michael Schaefer, PhD
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 240-627-3364
Email: mschaefer@niaid.nih.gov ​


DoD Spinal Cord Injury Translational Research Award


The SCIRP Translational Research Award mechanism was first offered in FY12. Since then, 21 Translational Research Award applications have been received, and 4 have been recommended for funding. The SCIRP Translational Research Award is intended to support translational research that will accelerate the movement of promising ideas in spinal cord injury research into clinical applications. Observations that drive a research idea may be derived from a laboratory discovery, population-based studies, or a clinician’s first-hand knowledge of patients and anecdotal data. While the ultimate goal of translational research is to move an observation forward into clinical application, Principal Investigators (PIs) should not view translational research as a one-way continuum from bench to bedside. The research plan must involve a reciprocal flow of ideas and information between basic and clinical science. Developmental pathways for translational research that may be useful for designing translational research studies for support under this mechanism may be found at http://www.cancer.gov/aboutnci/trwg/Pathways-to-Clinical-Goals. Applications must include preliminary and/or published data that is relevant to SCI and the proposed research project. Optional Qualified Collaborator: The FY14 SCIRP strongly encourages multidisciplinary collaborations among academic scientists and clinicians, industry scientists, the military Services, the VA, and other federal Government agencies. Collaborations with early-career investigators in the SCI field are encouraged. Although more than one collaborator may participate in the application, only one may be named for this option. The PI must submit a Statement of Collaboration that clearly identifies the collaborating investigator and addresses how each of the criteria listed below are met. Additionally, the collaborator must provide a biographical sketch (see Section II.C.3, Research and Related Senior/Key Person Profile) and a letter of collaboration (see Section II.C.2, Attachment 9: Statement of Collaboration) describing his/her involvement in the proposed research project.  It should be clear that the success of the proposed research project depends on the complementary skills and contributions of both the PI and collaborator.  The collaborator must significantly contribute to the proposed research project such that it could not be accomplished without his/her involvement. ○ A proposed research project in which the collaborator merely supplies tissue samples or access to patients will not meet the intent and will not be qualified for the higher level of funding. ○ At least a 10% level of effort is required of the collaborator. Contribution of the collaborator should be reflected in the application’s budget.  The collaborator must be in a position with freedom to pursue independent research goals without formal mentorship.

    Letter of Intent Due Date: Not applicable
    Application Due Date: Oct 30, 2014 

Scientific/Research Contact:​
CDMRP Help Desk 301-682-5507, help@eBRAP.org 
Dept. of the Army -- USAMRAA 301-619-7144


Translational Research to Help Older Adults Maintain their Health and Independence in the Community

R21: PA-14-159 (link)

R01: PA-14-161 (link)

This Funding Opportunity Announcement (FOA) invites applications using the R01 award mechanism for translational research that moves evidence-based research findings toward the development of new interventions, programs, policies, practices, and tools that can be used by organizations in the community to help older adults remain healthy and independent, productively engaged, and living in their own homes and communities.  The goal of this FOA is to support translational research involving collaborations between academic research centers and community-based organizations with expertise serving or engaging older adults (such as city and state health departments, city/town leadership councils, educational institutions, workplaces, Area Agencies on Aging, and organizations funded or assisted by the Corporation for National and Community Service) that will enhance our understanding of practical tools, techniques, programs and policies that communities across the nation can use to more effectively respond to needs of the aging population. 

    Letter of Intent Due Date: Not applicable
    Application Due Date: Standard dates by 5PM CT (until May 8, 2017)

Scientific/Research Contact:​

Jonathan W. King, Ph.D.
National Institute on Aging (NIA)
Telephone: 301-402-4156 
Email: kingjo@nia.nih.gov

Mary Rodgers, Ph.D.
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Telephone: 301-402-1337
Email: rodgersmm@mail.nih.gov​


Biomedical Technology Research Resource (P41)
   PAR-14-023      Pre-Application
   PAR-14-021​   Full Proposal

This funding opportunity announcement (FOA) encourages grant applications for national Biomedical Technology Research Resources. These Resources conduct research and development on new technologies and new/improved instruments driven by the needs of basic, translational, and clinical researchers. The Resources are charged to make their technologies available, to train members of the research community in the use of the technologies, and to disseminate these technologies and the Resource’s experimental results broadly. New applicants are strongly encouraged to submit a pre-application to PAR-14-023. The pre-application process provides feedback regarding the appropriateness for this program and competitiveness of a potential application.

    Letter of Intent Due Date: Not applicable
    Application Due Date: Sep 25, 2014; Jan 25, 2015; May 25, 2015; 
    Sep 25, 2015; Jan 25, 2016; May 25, 2016; Sep  25, 2016, by 5:00 PM​

Scientific/Research Contact:​
Douglas M. Sheeley, Sc.D. 
National Institute of General Medical Sciences (NIGMS)
Telephone: 301-451-6446 
Email: sheeleyd@mail.nih.gov

NEI Audacious Goal Initiative:  Addressing Technical Needs and Opportunities for Imaging the Visual System (U01)

RFA-EY-14-001

The NEI Audacious Goal Initiative (AGI) strategic planning process selected the single audacious goal (AG) of regenerating neurons and neural connections in the eye and visual system.  This AG speaks to two conditions, loss of photoreceptor cells (PRC) by disease or injury and damage to retinal ganglion cells (RGC) as occurs in glaucoma or optic neuropathy.  The AGI process also identified two areas of high programmatic priority, developing new treatments for eye disease using molecular approaches and understanding the intersection of aging and the biologic mechanisms of eye disease. The purpose of this Funding Opportunity Announcement (FOA) is to encourage submission of new, innovative, transformative projects to address the technical needs and opportunities in the field of visual system imaging in order to focus and enable research efforts towards achieving the goals of the AGI.

    Letter of Intent Due Date: July 14, 2014
    Application Due Date: August 14, 2014, by 5:00 PM CT

Scientific/Research Contact:
Cheri Wiggs, Ph.D.
National Eye Institute (NEI)
Telephone: 301-451-2020
Email: wiggsc@mail.nih.gov

Disseminating and Implementing Evidence from Patient-Centered Outcomes Research in Clinical Practice Using Mobile Health Technology (R21)


This Funding Opportunity Announcement (FOA) invites applications for developmental research projects on using mobile health technology (mHealth) to facilitate the dissemination and implementation of findings from patient-centered outcomes research (PCOR) into clinical practice.  The purposes of this FOA are to develop and evaluate the effectiveness of novel approaches that use mHealth tools to enable the timely incorporation and appropriate use of PCOR evidence in clinical practice. 

    Letter of Intent Due Date: June 20, 2014
    Application Due Date: August 4, 2014, by 5:00 PM​

Scientific/Research Contact:
Scott Smith, Ph.D.
Agency for Healthcare Research and Quality
Center for Outcomes and Evidence
Telephone: 301-427-1511
Fax: 301-421-1520
E-mail address: Scott.Smith@ahrq.hhs.gov



Assessment of Prevention, Diagnosis, and Treatment Options – Fall 2014 Cycle

Letter of Intent: 9/5/2014
Application:11/4/2014
RFA TBA (2013 RFA)   

Improving Healthcare Systems – Fall 2014 Cycle

Letter of Intent: 9/5/2014
Application:11/4/201
RFA TBA (Spring 2014 RFA)   

Communication and Dissemination Research – Fall 2014 Cycle

Letter of Intent: 9/5/2014
Application:11/4/2014
RFA TBA (2013 RFA)  

Addressing Disparities – Fall 2014 Cycle

Letter of Intent: 9/5/2014
Application:11/4/2014
RFA TBA (2013 RFA)   

Improving Methods for Conducting Patient-Centered Outcomes Research – Fall 2014 Cycle

Letter of Intent: 9/5/2014
Application:11/4/2014
RFA TBA (Spring 2014 RFA​)  


Partnerships for Innovation: Accelerating Innovation Research- Technology Translation


The NSF Partnerships for Innovation (PFI) program within the Division of Industrial Innovation and Partnerships (IIP) is an umbrella for two complementary subprograms, Accelerating Innovation Research (AIR) and Building Innovation Capacity (BIC). Overall, the PFI program offers opportunities to connect new knowledge to societal benefit through translational research efforts and/or partnerships that encourage, enhance and accelerate innovation and entrepreneurship. The subject of this solicitation is PFI: AIR-Technology Translation (PFI: AIR-TT). The PFI: AIR-TT solicitation serves as an early opportunity to move previously NSF-funded research results with promising commercial potential along the path toward commercialization. Projects are supported to demonstrate proof-of-concept, prototype, or scale-up while engaging faculty and students in entrepreneurial/innovative thinking. WEBINAR: A webinar will be held within 6 weeks of the release date of this solicitation to answer any questions about this solicitation. Details will be posted on the IIP website (http://www.nsf.gov/eng/iip/pfi/air-tt.jsp) as they become available.

    Letter of Intent Due Date: September 02, 2014, March 13, 2015
    Application Due Date: 5PM CT, October 02, 2014, April 14, 2015

Scientific/Research Contact:
Scientific/Research Contact(s)
Barbara H. Kenny, Program Director, 
Telephone: (703) 292-4667
Email: bkenny@nsf.gov



Innovative Approaches for the Identification of Mitochondria-Cell Signaling Networks in Response to Environmental Stress (R21/R33)


This Funding Opportunity Announcement (FOA) supports the development of technologies and experimental models to more precisely track signaling between the mitochondria and other cellular processes under environmental stress conditions, including mitochondrial-nuclear signaling with respect to epigenetic regulation, DNA damage response, or response to oxidative stress. This FOA uses the R21/R33 Phased Innovation Award mechanism to develop new technologies and experimental models to elucidate mitochondrial-cell signaling. Technologies developed in the R21 phase may include more sensitive reagents for detection of specific reactive oxygen or nitrogen species, enhanced approaches for metabolic flux analysis, and expanded in vitro or experimental models for identifying alterations in signaling pathways in response to environmental stressors. Successful completion of milestones outlined in the R21 phase will enable investigators to be considered for the R33 phase to conduct additional pilot testing and validation of these technologies using environmental stressors to probe bidirectional communication resulting in either altered cellular programming or mitochondrial function or both.   

    Letter of Intent Due Date: August 15, 2014
    Application Due Date: September 15, 2014, by 5:00 PM CT

Scientific/Research Contact:
Daniel Shaughnessy, PhD
National Institute of Environmental Health Sciences (NIEHS)
Telephone: 919-541-2506
Email: shaughn1@niehs.nih.gov


Molecular and Cellular Characterization of Screen-Detected Lesions (U01)

RFA-CA-14-010  Research Proposals
RFA-CA-14-011​  Coordinating Center and Data Management Group (U01)

The goal of this Funding Opportunity Announcement (FOA), is to solicit applications from independent, multi-disciplinary teams to undertake a comprehensive molecular and cellular characterization of tumor tissue, cell, and microenvironment components to distinguish screen-detected early lesions from interval and symptom-detected cancers.  Individual research teams will pursue one or more aspects of molecular and cellular analysis of one or more of the specified tumor sites (breast, prostate, lung, melanoma, and pancreas).  Use of enabling approaches and technologies will be encouraged to determine both the cellular and molecular phenotypes of early lesions, to assess the degree to which the behavior of these lesions is predictable or stochastic, and to allow better predictions of the fate of early lesions.  To achieve the goal of a comprehensive characterization of screen-detected lesions, each research team should include cancer researchers and clinicians with multi-disciplinary expertise.  The individual research teams funded through this FOA are expected to participate in a collaborative Consortium.  In addition to individual studies, a major collaborative effort within the Consortium will be the establishment of an annotated biospecimen repository of screen-detected lesions and interval cancers.  Research teams will also be expected to share results freely within the Consortium, and develop trans-Consortium collaborative projects that make use of the combined expertise and technological capabilities present in all of the teams.  During the final selection of the teams to be funded through this FOA, NCI will, if possible, attempt to ensure that most of the specified tumor sites are represented.

    Letter of Intent Due Date: August 17, 2014
    Application Due Date: September 17, 2014, by 5:00 PM CT

Scientific/Research Contact:
For questions related primarily to cancer prevention research, contact:

Sudhir Srivastava, Ph.D., M.P.H.
National Cancer Institute (NCI)
Telephone: 240-276-7028
Email: srivasts@mail.nih.gov

For questions related primarily to cancer biology research, contact:

Suresh Mohla, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-6220
Email: mohlas@mail.nih.gov


Onsite Tools and Technologies for Heart, Lung, and Blood Clinical Research Point-of-Care SBIR 

R43/R44 RFA-HL-14-011

The purpose of this Funding Opportunity Announcement (FOA) is to support research using advanced technologies to develop novel point-of-care (POC) devices and implement existing technologies in clinical settings with a goal to guide diagnostic and therapeutic efforts for the heart, lung, blood (HLB) and sleep disorders. 

Budget
R43/R44 and R41/R42:   Budget: Budgets up to $225,000 total costs for Phase I and up to $1,500,000 total costs for Phase II may be requested. 

    Letter of Intent Due Date(s)
     R43/R44 Sept.15, 2014; March 16, 2015; Sept. 15, 2015 
     R41/R42 Not applicable

     Application Deadline(s)
     ​R43/R44 Oct.15, 2014; April 16, 2015; Oct.15, 2015;by 5PM
     R41/R42 Oct. 15, 2014; Oct.15, 2015, Oct.15, 2016, by 5PM

Scientific/Research Contact:​ See RFAs
R43/R44 RFA-HL-14-011
R41/R42 RFA-HL-14-017​


Congressional Directed Medical Research Programs 

Several of the Congressional Directed Medical Research Programs have released Program Announcements. Some of the mechanisms have pre-proposal (LOI) due date as early as May 13, 2014.  Visit the CCTS Research Commons page dedicated to CDMRP Funding. The CCTS will facilitate Project Panels this month to aid in LOI review.  Utilize the experience of UAB faculty that have reviewed or been funded by the CDMRP. Contact us at: ccts@uab.edu.

Sponsor: DOD

Letter of Intent: Variable

Application Deadline: See specific RFA

Contact Information: ccts@uab.edu 

RFA:  CCTS Research Commons page dedicated to CDMRP Funding.​


Alabama Launchpad Small Business Innovation Research(SBIR) and the Small Business Technology Transfer Programs

Administered by the US Small Business Administration, through which many of the largest federal agencies award contracts and grants to small businesses.  The purpose of the Alabama SBIR/STTR Support Program is to increase the success rate and competitiveness of SBIR/STTR applicants in the state. The program will provide support in three ways:

  1. Raise SBIR/STTR awareness for Alabama-based small businesses through a statewide network of partners that will advocate and host introductory SBIR/STTR workshops

  2. Educate Alabama companies on how to compete for SBIR/STTR awards

  3. Provide one-on-one writing assistance and proposal strategy from an expert with decades of experience writing and reviewing SBIR/STTR proposals

Benefits

  • Beyond-the-basics training about SBIR and STTR Programs

  • How to prepare competitive proposals and proposal strategy

  • Avoiding common proposal mistakes

  • Federal agency focused workshops

  • Proposal evaluation

  • Individual writing assistance

Applicants can receive extensive proposal writing assistance for a chance to receive over $1 million in SBIR/STTR funding. Click here for more info.

Sponsor: Alabama SBIR/STTR Support Program

Letter of Intent: None

Application Deadline: Rolling

Contact Information: See RFA

RFA:  AL SBIR/STTR


Community Partnerships to Advance Research (CPAR)

R21: PA-14-141,  Exploratory/Developmental Grant

R01: PA-14-142,  Research Project Grant   

R15: PA-14-140,  Academic Research Enhancement Award (AREA)

This funding opportunity announcement (FOA) encourages researchers to partner with communities using Community Engaged Research (CEnR) methodologies that will enhance relationships leading to better interventions and positive health outcomes.     Research objectives aim to partner with a community entity on health issues that is of mutual concern, such as but not limited to:

  • Interventions/programs for health promotion/prevention
  • Interventions/programs leading to self-management in chronic conditions
  • Programs that target self or symptom management
  • Examine ways to enhance or implement sustainable health programs in community settings  

Sponsor: NIH

Letter of Intent: None

Application Deadline: Standard NIH Dates Apply (until May 8, 2017)

Contact Information: See RFA

RFA:  R21: PA-14-141,  Exploratory/Developmental Grant

R01: PA-14-142,  Research Project Grant   

R15: PA-14-140,  Academic Research Enhancement Award (AREA)​


Large Pragmatic Studies to Evaluate Patient-Centered Outcomes – Fall 2014 Cycle

 
PCORI is now accepting Letters of Intent (LOIs) through our second call for proposals to conduct large pragmatic clinical studies. We'll provide up to $90 million to fund approximately nine such studies, which are designed to address important questions faced by typical patients and clinicians. 

Patient-Centered Outcomes Research Institute (PCORI) seeks to fund pragmatic clinical trials (PCTs), large simple trials (LSTs), or large-scale observational studies that compare two or more alternatives for addressing prevention, diagnosis, treatment, or management of a disease or symptom; improving health care system–level approaches to managing care; or for eliminating health or healthcare disparities.  Proposed studies must address critical clinical choices faced by patients, their caregivers, clinicians, and/or delivery systems. They must involve broadly representative patient populations and be large enough to provide precise estimates of hypothesized effectiveness differences and to support evaluation of potential differences in treatment effectiveness in patient subgroups.  For this solicitation, PCORI is requiring that relevant patient organizations, professional organizations, and/or payer or purchaser organizations be included as partners and actively participate in the study. PCORI expects that most awards will be made for study designs that use randomization, either of individual participants or clusters, to avoid confounding bias. However, we recognize that exceptional opportunities may arise, by virtue of natural experiments and/or the existence of large registries, to address pragmatic questions using observational designs. This new PCORI program will not support applications to conduct cost-effectiveness analysis, evidence synthesis, or to study decision-support tools. 


    Letter of Intent Due Date: June 27, 2014 at 5:00 p.m. (ET)
    Invited Application Due Date: November 4, 2014, by 5:00 p.m. (ET)


Contact Information: 


NIH Bench-to-Bedside program

The Bench-to-Bedside (B2B) Program funds research teams seeking to translate basic scientific findings into therapeutic interventions for patients and to increase understanding of important disease processes.  The B2B Program accomplishes this mission by addressing barriers, such as the traditional silos between basic and clinical researchers in biomedical research, which can hinder progress toward finding new therapeutics for patients in need. B2B teams involve basic and clinical researchers, often from different NIH Institutes and Centers. In 2006, the B2B program's charge was expanded to unite the efforts of intramural and extramural NIH researchers. Intramural science refers to research that takes place on an NIH campus under the auspices of federal employees, while extramural research is funded by NIH and conducted by investigators and institutions outside of NIH.
 
Up to $135,000 per year for two years is available to support clinical research intramural/extramural partnerships.  All NIH intramural investigators are eligible to serve as project leaders on proposals which require partnership between a basic and clinical scientist.  The proposals can involve only intramural investigators, but priority will be given to proposals with intramural and extramural partners.  Extramural partners need to have an existing NIH grant which will be supplemented for successful applications. Extramural investigators are also invited to initiate proposals and serve as project leaders with an intramural partner who will be responsible for coordination of proposal submissions.
 
   Letter of Intent Due Date: June 18, 2014
    Invited Application Due Date: August 20, 2014

Contact Information:

Courtney Bell, MPA,Special Assistant to the Director
NIH Clinical Center, CRC 6-157
Phone: (301) 402-0102
Email: BenchtoBedside@mail.nih.gov

Pat Piringer, RN, MSN, Special Assistant to the Director
NIH Clinical Center, CRC 6-1530
Phone: (301) 402-2435
Email: BenchtoBedside@mail.nih.gov

Translational Programs in Lung Diseases (P01)


This Funding Opportunity Announcement (FOA) invites submission of Program Project (P01) applications from institutions/organizations that will perform collaborative, translational research with the goal of using mechanistic research as the basis for the rational design of clinical applications to improve prevention, diagnosis and/or treatment of lung diseases and sleep disorders. 

Award Budget: Less than $1.75 million per year direct costs (exclusive of F&A costs associated with consortia) for a maximum of $8.75 million directs costs over a five-year project period.


Letter of Intent Due Date: 30 days prior to the application due date
Application Due Date: 5pm CT - September 22, 2014; May 19, 2015; September 22, 2015; May 19, 2016; September 22, 2016; May 19, 2017

Scientific/Research Contact(s)
Patricia Noel, Ph.D.
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-0202
Email: noelp@nih.gov

Grants to Enhance Applicability of Mouse Models for Translational & Oncologic Research

PAR-14-241 R01 Research Projects to Enhance Applicability of Mouse Models for Translational Research
PAR-14-240 R01 Research Project Grant
PAR-14-239 ​U24 Oncology Models Forum (Collaborative Agreement)

The purpose of this set of Funding Opportunity Announcements (FOAs) is to invite applications for projects to expand and improve the utility of mouse cancer and tumor models for translational research. The NCI supports many hypothesis-driven, mechanistic R01 projects that employ mice, or develop and use mouse cancer models or human-in-mouse tumor models for many aspects of oncology research.  However, the NCI has not previously supported projects devoted to ensuring that mice and mouse models used for translational research questions are appropriate for those purposes and that the models provide reliable and informative data for patient benefit.  Applications could propose to overcome limitations of mouse and human-in-mouse oncology models, define a new translational use of models or mouse genetics for unmet needs, advance standard practices for modeling human cancers and tumors in mice and for validating and credentialing models, or develop widely applicable tool strains or resources that enable cross-species comparisons.

Letter of Intent Due Date: Not Applicable
Application Due Date: RFA Specific (below)

PAR-14-241 R01 5pm CT - August 3, 2014 then Standard dates apply 
(until May 8, 2017)
PAR-14-240 R01 5pm CT - August 3, 2014 then Standard dates apply (until May 8, 2017)
PAR-14-239 U24 5pm CT - August 7, 2014 and May 1, 2015

Scientific/Research Contact(s)
Cheryl L. Marks, PhD
National Cancer Institute (NCI)
Telephone: 240-276-6217
Email: marksc@mail.nih.gov

INTERNAL OPPORTUNITIES

Health Services Foundation - General Endowment Fund (HSF-GEF) Request for Applications

Statement of Purpose: The HSF-GEF grants are intended to enhance the infrastructure of Academic Health Center’s Patient-Oriented and Laboratory Research efforts, Clinical Care Program Development, and Medical Education Initiatives and for university-wide projects by providing funding from the Health Services Foundation’s General Endowment Fund.  

Intent of the HSF Source of Funds:  “The net spendable income from the HSF-GEF is intended generally for the benefit of the HSF and the UAB School of Medicine; however, the HSF Board of Directors may allocate net spendable income for other UAB purposes.  In general, funds from the HSF-GEF should be directed towards research, educational, and clinical programs which are deemed in the best interest of the UAB Medical Center and for UAB university-wide projects which are consistent with institutional priorities and with the Articles of Incorporation of the HSF.”  (Source: HSF Board Executive Report in Distribution of Revenues upon sale of United Healthcare Corporation Stock.)  HSF-GEF Scholar Awards were created in 2002 to serve as the appropriate mechanism for funding requests pertaining to the recruitment of new faculty.  The Scholar Awards are administered through a separate process and therefore, the HSF-GEF Awards referenced above will not be allocated for recruitment purposes.

Schedule of Deadlines  

  • May 1, 2014 Application packets to Deans for distribution
  • July 21, 2014, 4PM Applications due to SOM Dean's Office 
  • August 15,  2014 GEF Review Group recommendations completed
  • September 2014 GEF Committee meeting (TBD)  
  • October 27, 2014 UAHSF Board decision released
  • November 1, 2014 Funding available for use by awardees

Sponsor: HSF-GEF

Due Date: 7/21/2014 5:00 PM

Contact Information:

Angi White, University of Alabama Health Services Foundation /

JNWB Suite 502

P:934-9296  

E: angiwhite@uabmc.edu

RFA: 2014 HSFGEF Application


Requests for Information

Request for Information: Collaborative Translational Research Consortium to Develop T4 Translation of Evidence-based Interventions 


The NHLBI is considering creating a research consortium to evaluate methods for increasing the uptake and application of evidence-based interventions for heart, lung and blood diseases and sleep disorders. This Request for Information (RFI) seeks advice from experts in translating and disseminating evidence-based interventions into clinical practice (T4 Translation) on the design of an effective and practical Research Network that would be "disease agnostic." The objective is to provide an expert infrastructure platform for research on translation related to a variety of diseases and conditions within the mission of the NHLBI. Individuals, institutions and organizations with experience in translation and implementation science and clinical trials networks are invited to submit comments.

    Release DateJuly 2, 2014
    Response Date: August 29, 2014

Please direct all responses a/o inquiries to: 
Dr. Peter G. Kaufmann
National Heart Lung and Blood Institute (NHLBI)
Email: kaufmannp@nhlbi.nih.gov


Request for Information (RFI): Public-Private Partnerships for Organ Systems and Platforms Developed by Microphysiological Systems (MPS) Investigators


The National Center for Advancing Translational Sciences (NCATS) seeks information from key stakeholders regarding potential public-private partnerships for the commercialization of organ system platforms (i.e., "organs on chips"), bioengineered platforms, and related items (e.g., cell sources, perfusion media, pumps) developed by the NIH-supported investigators of the Micro-physiological Systems Program (MPS). Key stakeholders include investigators who are funded to develop organ system platforms or related components, potential commercial partners, funding and regulatory agencies. Specifically, the NCATS requests information regarding the types of public-private partnerships that are most effective for product development, distribution and commercialization; and ideas for how best to disseminate information regarding the availability of organ system platforms to a targeted, relevant audience..

    Release DateJuly 2, 2014
    Response Date: July 31, 2014

Please direct all responses a/o inquiries to: 
Danilo A. Tagle, Ph.D. 
National Center for Advancing Translational Sciences (NCATS) 
Telephone: 301-594-8064
Email: NCATSMPS@mail.nih.gov

Kristin Fabre, Ph.D.
National Center for Advancing Translational Sciences (NCATS) 
Telephone: 301-594-7609

​​​​​​​
SHARPEN YOUR SCIENCE:

For any internal or external application:

You write the science, let the CCTS do the rest.  Contact ccts@uab.edu for more information.


Tip of the Week!

Plan ahead!  Take a look at all the timelines in the Strategy for NIH Funding​. This is helpfulf to anticipate required actions and make sure your plans are on track. Contact the CCTS Research Commons (ccts@uab.edu; 4.7442) to learn more.


UAB Policy when Number of Submissions is Limited by Sponsor

Some sponsors restrict the total number of applications submitted per institution, school, and/or discipline. When the sponsor's program guidelines stipulate a limit, an internal review process may be necessary to determine the applicant(s) or proposal(s) to represent UAB.​​  Please see these guidelines​.  If you have any questions, please contact ccts@uab.edu.